Company Overview - The Fortune Teller is a team of two analysts with over 30 years of combined market experience [1] - One of the principals is a formerly licensed investment advisor with a background in asset management [1] - The team holds BAs in Accounting & Economics and Computer Sciences, as well as MBAs, which they use to inform their stock selections [1] Service Offerings - The Fortune Teller leads the investing group Wheel of Fortune, which provides actionable trading ideas across all asset classes, sectors, and industries [1] - The service aims to be a one-stop-shop for investment and portfolio ideas while educating subscribers [1] - Features include the Funds Macro Portfolio (ETFs and CEFs) for less active investors and the Single Macro Portfolio (single equity focused) for more active investors [1] - The service also offers educational content and a live chat room for discussions with like-minded investors and The Fortune Teller team [1]

SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT. Investors and other interested parties can access the live audio webcast through the Investor Relations section of Legend's websi ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we put Legend Biotech Corporation (NASDAQ: LEGN ) in the spotlight for the first time since the first month of 2024. When we last looked at Legend in January, the company wa ...

传奇生物（LEGN） 更新报告 买入 2024 年 11 月 27 日 研发进度领先，销售开始逐步放量 24 年 Q3 CARVYKTI 收入增长 88%：西达基奥仑赛 CARVYKTI 3 季度收入同比+88%至 2.86 亿美元（环比+53%），按照和强生的海外对 半收入分成协议， 24 年 3 季度合作收入为 1.43 亿美元，另有诺华 DLL3 Car-t 的 0.17 亿美元的许可收入，公司 3 季度的收入为 1.6 亿 美元，同比增长 67%，毛利率达 65.4%。3 季度公司经营利润亏损 0.7 亿美元，净利润亏损 1.25 亿美元。公司现金 12 亿美元，将提供资金 支持至 26 年实现营业利润。2025 年底预计将达到年产 10000 剂的目 标，并有望在未来 2-3 年继续增加产能。 但玉翠 852-253219539 Tracy.dan@firstshanghai.com.hk 高小迪 852-25321960 xiaodi.gao@firstshanghai.com.hk 唯一显著延长总生存期疗法：CARVYKTI 是唯一临床证明与标准疗法 相比可显著延长 MM 患者早在二线治疗后的总 ...

交银国际研究 财务模型更新 资料来源：FactSet，公司资料，交银国际预测 收盘价 目标价 潜在涨幅 美元 40.18 美元 76.00 +89.1% 医药 2024 年 11 月 13 日 传奇生物 (LEGN US) 3Q24 业绩好于预期，市场对竞争格局变化过度悲观，维持买入评级 3Q24 整体好于预期：公司 3Q24 收入同比增长 67%至 1.60 亿（美元，下 同），主要得益于合作收入的快速增长（1.43 亿，+88%），Carvykti 销售 环比增 54%/同比增 88%至 2.86 亿（此前强生已披露），公司预计产品销 售将在 4Q24 保持环比增长态势，得益于强劲二线治疗需求、市场份额扩 张和产能爬坡。门诊给药患者比例快速提升至 48%（2Q/1Q24：接近 45%/ 约 35%），明显高于其他已上市 CAR-T 药物，得益于优异的安全性（CRS 副作用发作时间延后且更易于管理）。授权收入0.17 亿，主要来自诺华授 权协议。产品生产毛利率快速提升，达到 63%（2Q/1Q24：37%/ 51%）， 研发/销售/管理费用分别同比-0.3%/+110%/+26%，销售费用大幅增长主因 2- ...

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Mythili Koneru - Chief Medical Officer Steve Gavel - Senior Vice President, Commercial Development, U.S. & Europe Conference Call Participants Gena Wang - Barclays Kelly Shi - Jefferies Jessica Fye - JPMorgan Kostas Biliouris - BMO Capital James S ...

Legend Biotech Corporation Sponsored ADR (LEGN) reported $160.21 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 66.9%. EPS of -$0.34 for the same period compares to -$0.17 a year ago.The reported revenue represents a surprise of +10.72% over the Zacks Consensus Estimate of $144.7 million. With the consensus EPS estimate being -$0.56, the EPS surprise was +39.29%.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 6-K ________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 12, 2024 Commission File Number: 001-39307 ________________________________ Legend Biotech Corporation | --- | |---------------------------------------------------------------------------------------------------| | | | | | (Exact Name ...

Shares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma MRD data to be featured in oral presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting SOMERSET, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residual disease (M ...